4-Sulfanyl-N,N-dimethylbenzamide | 62778-80-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Sulfanyl-N,N-dimethylbenzamide
• 英文别名: N,N-dimethyl(4-sulfanylphenyl)carboxamide；4-mercapto-N,N-dimethyl-benzamide；N,N-dimethyl 4-mercaptobenzamide；4-[N,N-dimethylcarbamoyl]thiophenol；4-dimethylcarbamoylthiophenol；N,N-Dimethyl-4-sulfanylbenzamide
• CAS: 62778-80-7
• 化学式: C₉H₁₁NOS
• 分子量: 181.258
• InChiKey: MNQCDZMHOAKFDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Sulfanyl-N,N-dimethylbenzamide 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 14.0h， 生成
  参考文献：
  名称：

  通过反离子控制的相转移相互转化的多态动态配位化合物

  摘要：

  我们研究了一系列动态弱链接方法（WLA）配合物，它们可以在两种不混溶的溶剂之间穿梭，并可以通过离子交换在两种结构状态之间切换。在这里，我们确定了疏水性阴离子将阳离子，两亲性络合物从水相转移到有机相，而氯离子源则逆转了这一过程。由于WLA配合物具有动态的金属配位特性，可以调节这些配合物（单-或双-）的密度，因为它们分配到不同的相中。另外，我们发现带有不同供体强度的配体的杂合配合物优先重排为两个均相配合物，这些相配合物被相分以最大化更强配位键的数量。在使用一种溶剂的系统中未观察到此行为，强调了多相溶剂环境中半不稳定配体的动态和刺激响应特性。综上所述，这项工作表明，高度可重构的WLA模式可以实现双相反应网络的设计或由直接的盐复分解反应驱动的化学分离。

  DOI：

  10.1021/acs.inorgchem.0c03708
• 作为产物：
  描述：

  4-巯基苯甲酸 在 sodium methylate 作用下， 以 甲醇 、 乙二醇二甲醚 为溶剂， 反应 9.0h， 生成 4-Sulfanyl-N,N-dimethylbenzamide
  参考文献：
  名称：

  Synthesis and structure–activity relationship of new cytotoxic agents targeting human glutathione-S-transferases

  摘要：

  The 6((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (NBDHEX, 1), a "suicide inhibitor" of the glutathione-S-transferase GSTP1-1, showed pro-apoptotic properties in tumor cells, but in vivo studies were limited by poor bioavailability and high affinity towards GSTM2-2, expressed in many non-cancerous tissues. Here we describe the synthesis and biological characterization of new 1 analogs (2-40), in which the hydroxyhexyl portion at the C4-sulfur atom has been replaced with phenyl-containing moieties as well as substituted alkyl chains. Some of the new compounds displayed 10-100 times increased water-solubility (8, 11, 17, 26-28, 34, 35), and most of them showed higher GSTP1-1 selectivity (2-20, 23-26, 31-33, 35) than 1. The presence of a phenyl ring with polar substituents is in general associated, with some exceptions (23, 24) to low cytotoxicity in osteosarcoma U-2OS cells. Differently, some alkyl derivatives possess cytotoxicity comparable (26, 34,35) or higher (30, 32) than 1. Among the novel compounds, selected ones (26, 27, 34, and 35) deserve further investigation for their anticancer potential. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.10.033

文献信息

• Electronic properties of para-substituted thiophenols and disulfides from 13C NMR spectroscopy and ab initio calculations: relations to the Hammett parameters and atomic chargesElectronic supplementary information (ESI) available: all characterization data are tabulated in Table S1. A figure showing the dependence of the natural charge of the C1 atom of the disulfides on the 13C NMR chemical shift is also provided. See http://www.rsc.org/suppdata/nj/b3/b300048f/
  作者：Raghvendra S. Sengar、Victor N. Nemykin、Partha Basu

  DOI：10.1039/b300048f

  日期：——

  of para-substituted benzene thiols and the corresponding disulfides were synthesized and characterized by 1H NMR, 13C NMR, and IR spectroscopies. Geometries of all sixteen thiols and fourteen disulfide compounds were optimized at the B3LYP/6-31G(d) level, while the electronic structure and the 13C isotropic shifts were calculated by ab initio Hartree-Fock method coupled with the Gauge-Independent Atomic

  大量的对位取代苯硫醇和相应的 二硫化物 被合成和表征 1 H NMR， 13 C NMR和红外光谱。全部十六个的几何硫醇 和十四 二硫化物在B3LYP / 6-31G（d）水平上对化合物进行了优化，而电子结构和13 C各向同性位移是通过从头算Hartree-Fock方法，不依赖于规规的原子轨道（GIAO）算法和6- 31 + G（d，p）基集。计算出的13 C NMR各向同性位移与实验数据表现出令人钦佩的一致性（δrmsd〜4.6 ppm）。对位取代碳的化学位移与Hammett常数（σp和σp +）呈线性关系。使用这种方法，树突的σp +常数配体对于2（n）和2（o）分别估计为0.25和0.24 。此外，硫原子上的NBO电荷在σp +参数下表现出潜在的响应。硫代酚基硫上的原子电荷随取代基的吸电子能力而变化，但是，电荷随吸电子能力的增加而增加。
• Substituted N-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
  申请人：AstraZeneca AB

  公开号：US06689909B1

  公开（公告）日：2004-02-10

  A compound of formula (I) wherein: n is 1 or 2; R1 is chloro, fluoro, bromo, methyl or methoxy; R2 is as defined within; R3 is as defined within; and R4 is hydrogen or fluoro; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.

  化合物的化学式（I），其中：n为1或2；R1为氯、氟、溴、甲基或甲氧基；R2如定义；R3如定义；R4为氢或氟；或其药学上可接受的盐或体内可水解的酯。描述了在温血动物（如人类）中使用化合物的化学式（I）来提高PDH活性。详细描述了化合物的化学式（I）的制备的药物组合物、方法和过程。
• Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
  申请人：——

  公开号：US20030207889A1

  公开（公告）日：2003-11-06

  Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity.

  具有MMP和TNF抑制活性的羟肟酸和羧酸衍生物。
• Heteroarylcarbamoylbenzene derivative
  申请人：IIno Tomoharu

  公开号：US20060167053A1

  公开（公告）日：2006-07-27

  Compounds represented by formula (I): as well as their pharmaceutically acceptable salts are disclosed. The compounds are useful as glucokinase activating agents for the treatment of diabetes and related conditions. Compositions and methods of treatment are also included.

  公式（I）所代表的化合物及其药学上可接受的盐被披露。这些化合物可用作激活葡萄糖激酶的药剂，用于治疗糖尿病及相关疾病。还包括治疗组合物和方法。
• Novel 2-pyridinecarboxamide derivatives
  申请人：Mitsuya Morihiro

  公开号：US20060258701A1

  公开（公告）日：2006-11-16

  The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，具有激活葡萄糖激酶的效果，并可用作糖尿病治疗剂，其化学式表示为（I）：[其中X1表示氮原子、硫原子、氧原子或类似物；R1表示6-至10-成员芳基基团、5-至7-成员杂芳基基团或类似物；D表示氧原子或硫原子；R和R3相同或不同，分别表示氢原子、低碳基或类似物；式（II）表示可选取代的5-至7-成员杂芳基团或类似物；式（III）表示单环或双环杂芳基团]或其药学上可接受的盐。